Clinicalpathological and prognostic significance of survivin expression in renal cell carcinoma: a meta-analysis
Metrics: PDF 1334 views | HTML 1553 views | ?
Zhichen Pu1,2,*, Guang-Zhen Wu1,*, QiFei Wang1
1Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
2State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China
*These authors have contributed equally to this work
QiFei Wang, email: [email protected]
Keywords: survivin, renal cell carcinoma, meta-analysis, prognosis
Received: August 19, 2016 Accepted: November 07, 2016 Published: February 04, 2017
Background: In recent years, survivin expression had been investigated as a prognostic biomarker for renal cell carcinoma (RCC), however, the results were conflicting. This study was aimed to explore the association between survivin expression and clinicalpathological features and the prognostic value for cancer-specific survival (CSS) and overall survival (OS) in RCC.
Results: Eleven studies with 1,697 subjects were included in this meta-analysis. The results showed that survivin expression was associated with higher tumor grade (OR=4.25, 95%CI: 3.04-5.95, p<0.001), advanced tumor stage (OR=3.83, 95%CI: 2.01-7.3, p<0.001) and lymph node metastasis (OR=4.19, 95%CI: 2.34-7.52, p<0.001), but had no association with age, gender or distant metastasis. In addition, survivin expression was also correlated with poor CSS (HR=2.08, 95%CI: 1.07-4.05, p=0.032) and poor OS (HR=2.28, 95%CI: 1.57-3.33, p<0.001).
Materials and Methods: Literature was searched by PubMed, Embase and Web of Science. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were extracted from eligible studies. Fixed or random effects model were used to calculate pooled HRs and 95%CIs according to heterogeneity.
Conclusions: This study demonstrated that survivin expression was associated with more aggressive clinical features and predicted poor CSS and OS in patients with RCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.